IN2010DE02164A - - Google Patents

Download PDF

Info

Publication number
IN2010DE02164A
IN2010DE02164A IN2164DE2010A IN2010DE02164A IN 2010DE02164 A IN2010DE02164 A IN 2010DE02164A IN 2164DE2010 A IN2164DE2010 A IN 2164DE2010A IN 2010DE02164 A IN2010DE02164 A IN 2010DE02164A
Authority
IN
India
Prior art keywords
formula
dpp
diabetes
inhibitors
synthesis
Prior art date
Application number
Other languages
English (en)
Inventor
Rajesh Jain
Jagadeeshwar R Rao
Siripragada Mahender Rao
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to IN2164DE2010 priority Critical patent/IN2010DE02164A/en
Priority to PCT/IN2011/000621 priority patent/WO2012035549A2/en
Priority to ARP110103328A priority patent/AR082971A1/es
Publication of IN2010DE02164A publication Critical patent/IN2010DE02164A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2164DE2010 2010-09-13 2011-09-12 IN2010DE02164A (xx)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN2164DE2010 IN2010DE02164A (xx) 2010-09-13 2011-09-12
PCT/IN2011/000621 WO2012035549A2 (en) 2010-09-13 2011-09-12 An improved process for the synthesis of beta amino acid derivatives
ARP110103328A AR082971A1 (es) 2010-09-13 2011-09-13 PROCESO PARA LA SINTESIS DE DERIVADOS DE b-AMINOACIDO

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2164DE2010 IN2010DE02164A (xx) 2010-09-13 2011-09-12

Publications (1)

Publication Number Publication Date
IN2010DE02164A true IN2010DE02164A (xx) 2015-07-24

Family

ID=44898127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2164DE2010 IN2010DE02164A (xx) 2010-09-13 2011-09-12

Country Status (3)

Country Link
AR (1) AR082971A1 (xx)
IN (1) IN2010DE02164A (xx)
WO (1) WO2012035549A2 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145333A1 (en) 2014-03-26 2015-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of sitagliptin and its intermediate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JP4530852B2 (ja) 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
DE60320008T2 (de) 2002-10-18 2009-06-18 Merck & Co., Inc. Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
WO2004043940A1 (en) 2002-11-07 2004-05-27 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004058266A1 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
CA2533893A1 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
US7238683B2 (en) 2003-11-04 2007-07-03 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2005247895A1 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1598341A1 (en) 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
EP1604662A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
EP1761532B1 (en) 2004-06-21 2013-04-10 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1784188B1 (en) 2004-08-23 2010-07-14 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE481969T1 (de) 2004-10-01 2010-10-15 Merck Sharp & Dohme Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
AR052879A1 (es) 2005-01-24 2007-04-11 Merck & Co Inc Procedimiento para preparar derivados de beta aminoacidos quirales por hidrogenacion asimetrica
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
WO2006104997A2 (en) * 2005-03-29 2006-10-05 Merck & Co., Inc. Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
EP1943215A2 (en) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
WO2007054577A1 (en) 2005-11-14 2007-05-18 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
WO2007063928A1 (ja) 2005-11-30 2007-06-07 Toray Industries, Inc. 新規な非環状アミンカルボキシアミド誘導体及びその塩
CN101925586B (zh) * 2008-01-24 2014-05-07 万能药生物有限公司 杂环化合物
EP2223923A1 (en) * 2009-02-25 2010-09-01 Esteve Química, S.A. Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof

Also Published As

Publication number Publication date
WO2012035549A3 (en) 2012-10-11
AR082971A1 (es) 2013-01-23
WO2012035549A2 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY155517A (en) Heterocyclic derivatives
NZ601121A (en) 5-alkynyl-pyrimidines
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
EA201390643A1 (ru) Кристаллические формы гидрохлорида (4a-r,9a-s)-1-(1h-бензоимидазол-5-карбонил-2,3,4,4a,9,9a-гексагидро-1h-индено[2,1-b]пиридин-6-карбонитрила и их применение в качестве ингибиторов hsd 1
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
EA201270302A1 (ru) Безводные формы производных пиридина
MX2012000178A (es) 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives